Skip to main content
Nath Biogene India Ltd. logo

Nath Biogene India Ltd. — Investor Relations & Filings

Ticker · NATHBIOGEN ISIN · INE448G01010 BSE.NS Agriculture, forestry and fishing
Open in API
Filings indexed 450 across all filing types
Latest filing 2024-05-08 Regulatory Filings
Country IN India
Listing BSE.NS NATHBIOGEN

About Nath Biogene India Ltd.

https://www.nathbiogenes.com

Nath Biogene India Ltd. specializes in the research, development, production, and marketing of high-quality hybrid seeds. The company maintains a diverse product portfolio encompassing field crops such as cotton, paddy, maize, jowar, and bajra, alongside a wide range of vegetable seeds including tomato, okra, and chili. With a strong emphasis on biotechnological innovation and plant breeding, the organization focuses on developing high-yielding, pest-resistant, and climate-resilient seed varieties to enhance agricultural productivity. Its operations are supported by extensive research and development facilities and a robust distribution network that ensures the delivery of advanced genetic materials to farming communities. The company leverages its technical expertise to provide integrated solutions aimed at improving crop quality and farmer profitability through sustainable agricultural practices.

Recent filings

Filing Released Lang Actions
Related Party Transactions
Regulatory Filings Classification · 95% confidence The document is a disclosure of Related Party Transactions on a consolidated basis for the half year ended 31st March 2024, pursuant to SEBI regulations. It includes detailed financial data about loans, advances, remuneration, and other transactions with related parties and key management personnel. The document references the half-year period and contains substantive financial data, not just an announcement or certification. Therefore, it is a regulatory disclosure related to financial results but not a full interim or annual report. Given the nature of the content focusing on related party transactions, it fits best under Regulatory Filings (RNS) as it is a compliance disclosure under SEBI regulations rather than a full financial report or other specific category.
2024-05-08 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is a detailed presentation titled 'Q4 & FY24 Investor Presentation' for Nath Bio-Genes (India) Limited, dated 8 May 2024. It includes comprehensive financial data such as income statements, segmental revenue, operating performance, and business highlights for the fiscal year ended 31 March 2024. The content includes forward-looking statements, business strategy, product information, and detailed financial metrics including revenue, EBITDA, PAT, and segment-wise performance. The document is lengthy (15,000 characters) and contains substantive financial data and analysis for a period shorter than a full fiscal year (quarter and full year). It is not merely an announcement or a certification but a full investor presentation with detailed financial and operational information. Therefore, the most appropriate classification is 'Investor Presentation' (IP).
2024-05-08 English
Dividend
Regulatory Filings
2024-05-08 English
Financial Result Updates
Regulatory Filings
2024-05-08 English
Disclosure under SEBI Takeover Regulations
Major Shareholding Notification Classification · 100% confidence The document is a disclosure under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, for the year ended March 31, 2024. It is a notification from the company to stock exchanges regarding shareholding information from promoters. This fits the definition of a Major Shareholding Notification (MRQ), which involves notification of changes in significant share ownership levels. The document is short and does not contain financial statements or detailed reports, but rather a regulatory disclosure about shareholding.
2024-05-07 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is a notification about an upcoming earnings conference call scheduled for May 9, 2024. It includes details such as the date, time, participants, and dial-in information. There is no actual financial data or results presented in the document, only an announcement of the call. According to the classification rules, a full transcript of the call would be classified as a Call Transcript (CT), but this document is only an announcement of the call, not the transcript itself. Therefore, the appropriate classification is Call Transcript (CT) as it relates to the conference call content, but since this is only the announcement, the best fit is still CT because it is directly related to the call. Confidence is high due to clear mention of earnings conference call details and no financial data present.
2024-05-06 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.